McGinnis Molly M, Siciliano Cody A, Jones Sara R
Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
J Neurochem. 2016 Sep;138(6):821-9. doi: 10.1111/jnc.13732. Epub 2016 Aug 15.
Cocaine is a commonly abused central nervous system stimulant that enhances dopamine (DA) neurotransmission through its ability to block dopamine transporters (DATs). Recent evidence suggests there may be an interaction between DATs and D2/D3 autoreceptors that modulates cocaine's effects. The purpose of this study was to explore how D2/D3 autoreceptors modulate the ability of cocaine to inhibit DA uptake through DATs on pre-synaptic DA terminals. Using fast-scan cyclic voltammetry in brain slices containing the nucleus accumbens core from male and female C57BL/6J mice, we first sought to examine the effects of global autoreceptor blockade using the non-selective D2/D3 autoreceptor antagonist, raclopride. We found that the ability of cocaine to inhibit DA uptake was increased by raclopride and that this effect was consistent across sexes. Furthermore, using D2 (L-741,626) or D3 (SB-277011-A) autoreceptor selective antagonists, we discovered that blockade of D3, but not D2, autoreceptors was responsible for the increased cocaine potency. Alterations in cocaine potency were attributable to alterations in uptake inhibition, rather than cocaine effects on vesicular DA release, suggesting that these results may be a product of a functional D3/DAT interaction apart from the canonical inhibitory actions of D3 autoreceptors on DA release. In addition, application of D2 (sumanirole) and D3 (PD 128907) autoreceptor-specific agonists had inverse effects, whereby D2 autoreceptor activation decreased cocaine potency and D3 autoreceptor activation had no effect. Together, these data show that DA autoreceptors dynamically regulate cocaine potency at the DAT, which is important for understanding cocaine's rewarding and addictive properties. We propose a model whereby presynaptic dopamine autoreceptors dynamically modulate cocaine potency through two separate mechanisms. We demonstrate that D2 agonists decrease cocaine potency, whereas D3 antagonists increase cocaine potency, likely through an allosteric mechanism outside of their canonical actions on dopamine release. These findings give important and novel insight into the contribution of D2/D3 autoreceptors to dopamine transporter function.
可卡因是一种常见的滥用中枢神经系统兴奋剂,它通过阻断多巴胺转运体(DATs)来增强多巴胺(DA)神经传递。最近的证据表明,DATs与D2/D3自身受体之间可能存在相互作用,从而调节可卡因的作用。本研究的目的是探讨D2/D3自身受体如何调节可卡因通过突触前DA终末上的DATs抑制DA摄取的能力。我们使用快速扫描循环伏安法,在来自雄性和雌性C57BL/6J小鼠的含有伏隔核核心的脑片中,首先试图研究使用非选择性D2/D3自身受体拮抗剂雷氯必利进行整体自身受体阻断的效果。我们发现,雷氯必利增强了可卡因抑制DA摄取的能力,且这种效应在两性中是一致的。此外,使用D2(L-741,626)或D3(SB-277011-A)自身受体选择性拮抗剂,我们发现阻断D3而非D2自身受体会导致可卡因效力增加。可卡因效力的改变归因于摄取抑制的改变,而非可卡因对囊泡DA释放的影响,这表明这些结果可能是D3/DAT功能性相互作用的产物,不同于D3自身受体对DA释放的经典抑制作用。此外,应用D2(舒马普坦)和D3(PD 128907)自身受体特异性激动剂产生了相反的效果,即D2自身受体激活降低了可卡因效力,而D3自身受体激活则没有影响。总之,这些数据表明DA自身受体动态调节DAT处的可卡因效力,这对于理解可卡因的奖赏和成瘾特性很重要。我们提出了一个模型,即突触前多巴胺自身受体通过两种不同机制动态调节可卡因效力。我们证明D2激动剂降低可卡因效力,而D3拮抗剂增加可卡因效力,这可能是通过其对多巴胺释放的经典作用之外的变构机制实现的。这些发现为D2/D3自身受体对多巴胺转运体功能的贡献提供了重要且新颖的见解。